Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR detectable phosphomonesters
Tim A. D. Smith*, M. Virginia C. L. Appleyard, Sheila Sharp, Ian N. Fleming, Karen Murray, Alastair M. Thompson
Dive into the research topics of 'Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR detectable phosphomonesters'. Together they form a unique fingerprint.